Welcome to our dedicated page for Surrozen news (Ticker: SRZN), a resource for investors and traders seeking the latest updates and insights on Surrozen stock.
Surrozen reports developments as a clinical-stage biotechnology company developing Wnt-based targeted therapeutics for sight-threatening ophthalmic diseases. Company updates center on its ophthalmology pipeline, including SZN-8141 and SZN-8143 in retinal diseases, antibody-engineering work, financial results, collaboration and license revenue, and research milestones tied to Boehringer Ingelheim.
Recurring announcements also cover healthcare investor conference presentations, Nasdaq inducement equity grants under the 2025 Equity Inducement Plan, and corporate governance or leadership matters that affect the company's public-company reporting profile.
Surrozen (Nasdaq: SRZN) published results indicating that its proprietary Wnt mimetic antibody, SZN-1326, demonstrated significant potential for treating inflammatory bowel disease (IBD). The study, published in Cellular and Molecular Gastroenterology and Hepatology, utilized a mouse model and showed that SZN-1326 effectively repaired injured colon epithelium while sparing healthy tissue. With no current therapies targeting epithelial repair, Surrozen is set to initiate Phase 1 clinical trials for SZN-1326 in Q3 2022, addressing a notable medical need in ulcerative colitis management.
Surrozen, Inc. (Nasdaq: SRZN) announced financial results for Q1 2022 and provided an update on its clinical pipeline. The company is set to initiate Phase 1 clinical trials for its lead product candidates, SZN-1326 targeting moderate to severe ulcerative colitis and SZN-043 for severe alcoholic hepatitis, in Q3 2022. Both candidates demonstrated substantial efficacy in preclinical trials without adverse effects. Surrozen is also advancing SZN-413 for retinal vascular diseases, with promising preclinical data supporting its potential. The firm remains focused on transitioning to a clinical-stage organization.
Surrozen, a biotechnology company focused on the Wnt pathway for tissue repair, announced that CEO Craig Parker will present at the BofA Securities 2022 Healthcare Conference on May 11 at 4 p.m. PT. The event will be available via a live audio webcast on Surrozen's Investor Relations website, with an archived version accessible later. Surrozen is developing targeted drug candidates for conditions such as inflammatory bowel disease and hearing loss, among others. For more details, visit Surrozen's official website.
Surrozen (Nasdaq: SRZN) announced promising preclinical data for its novel SZN-413, which targets retinal vascular diseases like diabetic retinopathy. Presented at the ARVO Annual Meeting, the data shows SZN-413 significantly reduced pathological neovascular tuft formation and avascular area in mouse models. Additionally, it demonstrated an ~80% reduction in retinal vascular leakage in rabbit models. This progress suggests a new therapeutic strategy in addressing retinal issues caused by diabetes, highlighting the potential of Wnt signaling in regenerative therapies.
Surrozen, Inc. (Nasdaq: SRZN) is advancing its lead therapeutic candidates, SZN-1326 and SZN-043, aimed at treating moderate to severe ulcerative colitis and severe alcoholic hepatitis, respectively. The company expects to initiate Phase 1 clinical trials in healthy volunteers by Q3 2022. SZN-1326 has shown promise in preclinical models for intestinal regeneration, while SZN-043 targets liver function improvement. Additionally, Surrozen continues to broaden its therapeutic pipeline with new candidates targeting vascular-associated retinopathies and potential therapies for dry eye and lung diseases.
Surrozen (Nasdaq: SRZN) has announced the initiation of Phase 1 clinical trials for its lead candidates, SZN-1326 and SZN-043, expected in Q3 2022. The company is also accelerating its research pipeline, including the nomination of SZN-413 for treating retinopathies. SZN-1326 aims to treat moderate to severe ulcerative colitis, while SZN-043 targets severe alcoholic hepatitis. Surrozen's proprietary technologies focus on Wnt pathway modulation for tissue repair, advancing into new therapeutic areas such as ophthalmology.
Surrozen, Inc. (Nasdaq: SRZN) announced plans to present a business update on January 13, 2022, at 9 a.m. ET during the 40th J.P. Morgan Healthcare Conference. The virtual presentation will cover advancements in its pipeline, focusing on drug candidates targeting the Wnt pathway for tissue repair and regeneration. Surrozen is developing specific antibodies for various conditions, including inflammatory bowel disease and neurological disorders. The presentation will be accessible via the Company's Investor Relations website.
Surrozen, Inc. (Nasdaq: SRZN) reported its Q3 2021 financial results, marking a pivotal year as the company began trading publicly. Key highlights include plans for Phase 1 clinical trials for SZN-1326 and SZN-043 in 2022, targeting ulcerative colitis and alcoholic hepatitis. Surrozen's cash position improved to $135.4 million, while research and development expenses rose to $10.4 million for Q3 2021 due to increased external costs. Despite this, the company reported a net loss of $14.0 million for the quarter, compared to $8.6 million in Q3 2020.
Surrozen (Nasdaq: SRZN) has presented encouraging data from its liver disease program at The Liver Meeting 2021. The preclinical studies of SZN-043 demonstrated improved liver metabolic function in mice, with promising non-invasive serum markers for Wnt pathway activation and liver regeneration. Highlights include serum alkaline phosphatase increases, indicating target engagement, and an early increase in circulating angiogenin as a potential biomarker for liver regeneration. These findings support Surrozen's progress towards Phase 1 clinical trials.
Surrozen, a biotechnology firm listed on NASDAQ under the ticker SRZN, announced that CEO Craig Parker will speak at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22 at 10:00 a.m. ET. The event will be accessible via a live webcast on the Surrozen website, with an archived replay available later.
Surrozen focuses on developing drug candidates that selectively modulate the Wnt pathway, which is crucial for organ development and regeneration. Their proprietary technology aims to address various degenerative diseases and tissue injuries.